insights_auto
Outlook: 48.3% bullish·17.2% bearish
Go to analysischevron_right
NVS:NYSE
Novartis AG
$150.47
arrow_downward
-0.50%(-0.75) 1D
$150.00
arrow_downward
-0.31% (-0.47)bedtimeAfter hours
Closed: Nov 20, 4:00:03 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVS...
Open
$152.25
High
$152.70
Low
$150.24
Mkt. cap
305.32B
Avg. vol.
2.12M
Volume
2.24M
Dividend
3.15%
Quarterly dividend
$1.19
Ex-dividend date
Mar 10, 2026
P/E ratio
28.79
52-wk high
$170.46
52-wk low
$125.88
EPS
$5.23
Beta
0.39
Shares outstanding
2.03B
No. of employees
75K
Open
$152.25
High
$152.70
Low
$150.24
Mkt. cap
305.32B
Avg. vol.
2.12M
Volume
2.24M
Dividend
3.15%
Quarterly dividend
$1.19
Ex-dividend date
Mar 10, 2026
P/E ratio
28.79
52-wk high
$170.46
52-wk low
$125.88
EPS
$5.23
Beta
0.39
Shares outstanding
2.03B
No. of employees
75K
News stories
From web sources and news partners
ad-hoc-news.de
·
52 minutes ago
Novartis stock: 5% growth outlook and Cosentyx FDA approval
The Globe and Mail
·
4 hours ago
Barclays Remains a Hold on Novartis AG (NOVN)
Yahoo Finance
·
23 hours ago
Novartis CEO leans on surge of pipeline readouts to quell growth fears
ad-hoc-news.de
·
1 day ago
Novartis stock sets 5% sales growth target through 2031
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedMar 7, 1996
HeadquartersBasel, Basel City, Switzerland
SectorHealth Care
IndustryPharmaceutical industry
Websitenovartis.com